ERBB2 and hepatocellular carcinoma: For example, lapatinib was shown to be more effective for HER2-positive AFP-GC [15, 32], and ramucirumab was reported to be more effective for AFP-positive hepatocellular carcinoma (HCC) than for AFP-negative HCC [33].